Avience Biomedicals shares may make a strong debut as GMP signals 62% premium ahead of listing

Avience Biomedicals IPO, priced at Rs 208 per share, was subscribed 385.32 times with NIIs leading at 597.23 times, retail at 401.36 times and QIBs at 196.77 times. Grey market premium indicates a 62 percent listing premium. The company reported FY25 total income of Rs 45.97 crore and net profit of Rs 7.23 crore, and will use proceeds for a new manufacturing facility in UP and working capital needs.